Nearly 120,000 adults and children are hospitalized annually with neutropenia caused by cancer chemotherapy, at a cost of nearly $3 billion, according to the CDC (J Oncol Pract 2017;13[6]:e552–e561). Can prophylaxis be the next big breakthrough in managing these patients?
Febrile neutropenia (FN), defined by grade 4 neutropenia and fever greater than 38° C, is one of the most dose-limiting toxicities of cancer chemotherapy, said Gary Lyman, MD, MPH, a researcher and policy